A clinical trial update dated October 30, 2026 reports a change in status for a study involving ARO-INHBE. The trial, titled "A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus," is registered under identifier NCT06700538. It is listed as a Phase 1/Phase 2 study. According to the registry entry, the trial's current status is active, not recruiting. This means enrollment is not currently open to new participants, though the study is ongoing. No results or outcome data are included in this update. The event data provided does not specify findings, efficacy, or safety outcomes for ARO-INHBE in this population. This brief reflects only the status change recorded in the trial registry as of the listed date. Readers interested in this compound's development should note that glucagon, mentioned in connection with this therapeutic area, remains an approved product with its own separate regulatory history. For additional background on the compound discussed in this update, readers can consult the compound overview.
Phase 1/2 ARO-INHBE Trial Status Updated as of Oct 30, 2026
See the full glucagon overview
Source: https://clinicaltrials.gov/study/NCT06700538